Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, m… Read more
Theralase Technologies Inc. (TLTFF) - Total Liabilities
Latest total liabilities as of September 2025: $1.91 Million USD
Based on the latest financial reports, Theralase Technologies Inc. (TLTFF) has total liabilities worth $1.91 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Theralase Technologies Inc. - Total Liabilities Trend (2012–2024)
This chart illustrates how Theralase Technologies Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Theralase Technologies Inc. Competitors by Total Liabilities
The table below lists competitors of Theralase Technologies Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pixelworks Inc
NASDAQ:PXLW
|
USA | $23.60 Million |
|
Semen Baturaja Persero Tbk
JK:SMBR
|
Indonesia | Rp1.41 Trillion |
|
Dae Young Pkg
KO:014160
|
Korea | ₩67.04 Billion |
|
Perdana Karya Perkasa Tbk
JK:PKPK
|
Indonesia | Rp486.15 Billion |
|
Deutsche Rohstoff AG
XETRA:DR0
|
Germany | €312.78 Million |
|
NK Co. Ltd
KO:085310
|
Korea | ₩66.41 Billion |
|
Test Rite International Co Ltd
TW:2908
|
Taiwan | NT$29.27 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Theralase Technologies Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Theralase Technologies Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Theralase Technologies Inc. (2012–2024)
The table below shows the annual total liabilities of Theralase Technologies Inc. from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.18 Million | -13.99% |
| 2023-12-31 | $1.37 Million | +28.36% |
| 2022-12-31 | $1.07 Million | +22.12% |
| 2021-12-31 | $874.79K | +2.06% |
| 2020-12-31 | $857.13K | -46.92% |
| 2019-12-31 | $1.61 Million | -37.07% |
| 2018-12-31 | $2.57 Million | +100.90% |
| 2017-12-31 | $1.28 Million | +132.32% |
| 2016-12-31 | $549.74K | -30.03% |
| 2015-12-31 | $785.66K | +78.32% |
| 2014-12-31 | $440.58K | -49.18% |
| 2013-12-31 | $866.99K | -28.19% |
| 2012-12-31 | $1.21 Million | -- |